Stable injectable compositions of glp-2 peptide
US-2024415933-A1 · Dec 19, 2024 · US
Methods and compositions for treating hypoglycemic disorders
US9616108B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9616108-B2 |
| Application number | US-8112308-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 10, 2008 |
| Priority date | Jan 8, 2007 |
| Publication date | Apr 11, 2017 |
| Grant date | Apr 11, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention relates to methods of treating and ameliorating congenital and neonatal hyperinsulinism and post-prandial hypoglycemia, comprising the step of administering an antagonist of the Glucagon-Like Peptide-1 (GLP-1) receptor, e.g. a GLP-1 fragment or analog thereof.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating congenital hyperinsulinism in a subject having congenital hyperinsulinism associated with or due to a loss of function mutation in the K ATP channel, the method comprising the step of administering to said subject an effective amount of a peptide, wherein the amino acid sequence of the peptide consists of the amino sequence set forth in SEQ ID NO: 1. 2. The method of claim 1 , wherein said congenital hyperinsulinism is associated with a mutation in a gene encoding a sulfonylurea receptor (SUR-1). 3. The method of claim 1 , wherein said congenital hyperinsulinism is associated with a mutation in a gene encoding a Kir6.2. 4. The method of claim 1 , whereby administering is via intravenous, parenteral, oral, intraperitoneal, subcutaneous administration or a combination thereof. 5. The method of claim 1 , wherein said peptide is administered subcutaneously. 6. The method of claim 1 , wherein said peptide is administered intravenously. 7. The method of claim 1 , wherein said peptide is administered by infusion.
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9616108B2 cover?
- This invention relates to methods of treating and ameliorating congenital and neonatal hyperinsulinism and post-prandial hypoglycemia, comprising the step of administering an antagonist of the Glucagon-Like Peptide-1 (GLP-1) receptor, e.g. a GLP-1 fragment or analog thereof.
- Who is the assignee on this patent?
- Stoffers Doris, De Leon Diva D, Stanley Charles, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification A61K38/26. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 11 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).